Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Novel Therapeutic Target in Non-Small Cell Lung Cancer: Evaluation of the Efficacy of Yttrium-90 (Y-90) Fibroblast Activation Protein Inhibitor (FAPI) - A Phase II Study

NCT07500285 is registered in ClinicalTrials.gov with Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization as lead sponsor.

NCT NCT07500285
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07500285 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Novel Therapeutic Target in Non-Small Cell Lung Cancer: Evaluation of the Efficacy of Yttrium-90 (Y-90) Fibroblast Activation Protein Inhibitor (FAPI) - A Phase II Study
Lead sponsor
Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization
Phase
Phase 2
Overall status
Not yet recruiting
Start date
April 10, 2026
Completion date
November 15, 2027
Enrollment
10 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic lung carcinoma, non-small cell lung cancer